Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Disorders of Erythrocytes01:27

Disorders of Erythrocytes

2.4K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
2.4K
Multiple Allele Traits01:49

Multiple Allele Traits

38.4K
The Concept of Multiple Allelism
38.4K
Translation01:31

Translation

157.9K
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
157.9K
Translation01:31

Translation

18.9K
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
18.9K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

946
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
946
Hypoxia01:23

Hypoxia

2.3K
Hypoxia is a medical condition characterized by an inadequate oxygen supply to body tissues. It typically manifests as a bluish discoloration of the skin and mucosae, especially in fair-skinned individuals, when hemoglobin (Hb) saturation drops below 75%.
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
2.3K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026
Same author

When cure exists but access does not.

Nature medicine·2026
Same author

Patient-Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non-Transfusion-Dependent β-Thalassemia Treated in the BEYOND Trial.

European journal of haematology·2026
Same author

Efficacy and Safety of Prophylaxis With a Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease-A WIL-31 Study Sub-Analysis.

European journal of haematology·2026
Same author

Management of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources.

The Lancet. Haematology·2026
Same author

Thalassemia and hypercoagulability.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Feb 25, 2026

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

2.0K

タラセミア

Ali T Taher1, David J Weatherall2, Maria Domenica Cappellini3

  • 1Department of Internal Medicine, American University of Beirut Medical Centre, Beirut, Lebanon.

Lancet (London, England)
|August 5, 2017
PubMed
まとめ
この要約は機械生成です。

タラセミアや状細胞病などの遺伝性疾患は 共通しています 鎖の不均衡や鉄過量などの根本的な原因を標的とした新しい治療法を研究しています.

さらに関連する動画

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

2.8K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.5K

関連する実験動画

Last Updated: Feb 25, 2026

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

2.0K
Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

2.8K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.5K

科学分野:

  • 血液学
  • 遺伝学
  • 分子生物学

背景:

  • 遺伝性ヘモグロビン疾患は,タラセミアと状細胞疾患を含む,世界的に流行している単一性疾患です.
  • これらの疾患は,グロービン鎖の比率の不均衡,非有効なエリトポエーシス,慢性溶血性貧血,および鉄過負荷の合併症で表れます.
  • 現在の治療は 輸血,鉄のケラート,切除で 新しい治療法の研究が進行中です

研究 の 目的:

  • 遺伝性ヘモグロビン疾患の 病理生理学を見直す
  • 現在の管理戦略を議論する.
  • 分子や病原性要因を標的とした新興治療アプローチを強調する.

主な方法:

  • 遺伝性ヘモグロビン疾患に関する文献レビュー
  • 病理学的メカニズムの分析
  • 現在と新しい治療戦略の評価

主要な成果:

  • 遺伝性ヘモグロビン疾患は,グロービン鎖の不均衡と鉄過量を含む複雑な病理生理学を示します.
  • 輸血やケレーションのような 従来の治療は標準ですが 限界があります
  • 病気の根本的なメカニズムに対処するための新しい治療法が探求されています.

結論:

  • ヘモグロビン疾患の 分子基盤を理解することは 標的治療の開発に不可欠です
  • 新しい治療法は,鎖の不均衡を修正し,エリトポエーシスを改善し,鉄の調節障害を管理することを目的としています.
  • 進行中の研究により,遺伝性ヘモグロビン疾患の患者の治療結果が改善される可能性が期待されています.